Tuberc Respir Dis > Volume 60(3); 2006 > Article
Tuberculosis and Respiratory Diseases 2006;60(3):314-320.
DOI:    Published online March 1, 2006.
The Relationship between Heme Oxygenase-1 Expression and Response to Cisplatin Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer.
Doo Kyung Yang, Mee Sook Roh, Kyung Eun Lee, Ki Nam Kim, Ki Nam Lee, Pil Jo Choi, Jung Hee Bang, Bo Kyung Kim, Hyo Rim Seo, Min Ji Kim, Seul Ki Kim, Soo Keol Lee, Choon Hee Son
1Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
2Department of Pathology, Dong-A University College of Medicine, Busan, Korea.
3Department of Radiology, Dong-A University College of Medicine, Busan, Korea.
4Department of Thoracic and Cardiovascular Surgery, Dong-A University College of Medicine, Busan, Korea.
5Medical Research, Center for Cancer Molecular Therapy, Dong-A University College of Medicine, Busan, Korea.
The overall response (20-30%) to chemotherapy in non-small cell lung cancer (NSCLC) is quite poor. Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in heme degradation. There is increasing evidence suggesting that the induction of HO-1 might have an important protective effect against oxidative stress including cisplatin containing chemotherapy. This study retrospectively investigated the relationship between HO-1 expression and the response to chemotherapy containing cisplatinin advanced NSCLC patients. MATERIAL AND METHODS: The medical records including the responses to chemotherapy of fifty nine cases were evaluated retrospectively, and the tissue samples of these patients were immunohistochemically stained for HO-1. RESULTS: Forty three of the fifty nine patients(72.8%) showed positive staining for HO-1 in their cancer tissues. There was no significant difference according to the cell type, stage and tumor size. In addition, there was no correlation between HO-1 expression and the responses to chemotherapy. CONCLUSION: HO-1 expression in tumor tissue dose not predict the response to cisplatin containing chemotherapy in advanced NSCLC. Further prospective studies with a larger number of patients will be needed to confirm these results.
Key Words: Heme oxygenase-1, Non-small cell lung cancer, Cisplatin containing chemotherapy

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next